| 17/05 | Analysis-Amgen's antitrust woes spur wider pharmaceutical deal fears |  |
| 16/05 | US FTC sues to block Amgen's $27.8 bln deal for Horizon Therapeutics | |
| 15/05 | Insider Sell: Biomarin Pharmaceutical | |
| 04/05 | BioMarin to Participate in Bank of America 2023 Health Care Conference | |
| 28/04 | BIOMARIN PHARMACEUTICAL INC Management's Discussion and Analysis of Financial Conditio.. | |
| 26/04 | BioMarin Pharmaceutical Lifts Voxzogo's 2023 Sales Guidance Range to $380-$430 Million .. | |
| 26/04 | BioMarin Pharmaceutical Lowers Roctavian's 2023 Sales Guidance Range to $50-$150 Millio.. | |
| 26/04 | Biomarin : Q1 Earnings Snapshot | |
| 26/04 | BioMarin Pharmaceutical Q1 Non-GAAP Earnings, Sales Increase | |
| 26/04 | Earnings Flash (BMRN) BIOMARIN PHARMACEUTICAL Posts Q1 Revenue $596.4M | |
| 26/04 | Earnings Flash (BMRN) BIOMARIN PHARMACEUTICAL Posts Q1 EPS $0.60 | |
| 26/04 | BioMarin Announces Record Breaking First Quarter 2023 Results, Including 15% Year-over-.. | |
| 26/04 | BioMarin Pharmaceutical Inc. Reaffirms Earnings Guidance for the Year 2023 | |
| 26/04 | BioMarin Pharmaceutical Inc. Reports Earnings Results for the First Quarter Ended March.. | |
| 26/04 | MiNA Therapeutics Enters Research Collaboration with BioMarin Pharmaceutical to Advance.. | |
| 13/04 | Biomarin To Host First Quarter 2023 : 30pm ET | |
| 12/04 | Insider Sell: Biomarin Pharmaceutical | |
| 27/03 | BioMarin Pharmaceutical's Treatment for Duchenne Muscular Dystrophy Receives US FDA's O.. | |
| 27/03 | BioMarin Pharmaceutical Treatment for Duchenne Muscular Dystrophy Granted Orphan Drug S.. | |
| 17/03 | Sarepta slides as FDA about-turn on panel clouds gene therapy approval path | |
| 15/03 | Insider Sell: Biomarin Pharmaceutical | |
| 14/03 | BioMarin Pharmaceutical Inc. Will Present Updated Data Demonstrating the Long-Term Bene.. | |
| 08/03 | FDA Accepts BioMarin's Supplemental New Drug Application to Expand Use of VOXZOGO for I.. | |
| 07/03 | FDA Accepts BioMarin's Supplemental New Drug Application to Expand Use of VOXZOGO® (vos.. | |
| 07/03 | U.S. Food and Drug Administration Accepts BioMarin Pharmaceutical Inc.'s Supplemental N.. | |
| 07/03 | BioMarin Provides Update on FDA Review of ROCTAVIAN™ (Valoctocogene Roxaparvovec).. | |
| 07/03 | BioMarin Pharmaceutical Inc. Provides Update on FDA Review of ROCTAVIAN™ (Valoctoc.. | |
| 02/03 | BioMarin to Participate in Three Investor Conferences in March | |
| 28/02 | BioMarin Announces Record Fourth Quarter and Full Year 2022 Total Revenues Driven by St.. | |
| 27/02 | BIOMARIN PHARMACEUTICAL INC Management's Discussion and Analysis of Financial Conditio.. | |
| 27/02 | BioMarin Pharmaceutical Inc. Reports Earnings Results for the Full Year Ended December .. | |
| 27/02 | Biomarin : Q4 Earnings Snapshot | |
| 27/02 | BioMarin Pharmaceutical Reports Q4 Break-Even Results, Revenue Rises; Fiscal 2023 Outlo.. | |
| 27/02 | BioMarin Pharmaceutical Guides For Full Year 2023 EPS of $1.80-$2.05 on Revenue of $2.3.. | |
| 27/02 | Earnings Flash (BMRN) BIOMARIN PHARMACEUTICAL Posts Q4 Revenue $537.5M, vs. Street Est .. | |
| 27/02 | BioMarin Announces Record Fourth Quarter and Full Year 2022 Total Revenues Driven by St.. | |
| 27/02 | BioMarin Pharmaceutical Inc. Provides Financial Guidance for 2023 | |
| 27/02 | BioMarin Pharmaceutical Inc. Reports Earnings Results for the Fourth Quarter Ended Dece.. | |
| 15/02 | BioMarin Pharmaceutical to Participate Virtually at SVB Securities Global Biopharma Con.. | |
| 15/02 | Insider Sell: Biomarin Pharmaceutical | |
| 14/02 | BioMarin to Participate Virtually at SVB Securities Global Biopharma Conference on Febr.. | |
| 07/02 | Biomarin To Host Fourth Quarter And : 30 p.m. ET | |
| 19/01 | Insider Sell: Biomarin Pharmaceutical | |
| 09/01 | BioMarin Announces Stable and Durable Annualized Bleed Control for ROCTAVIAN in Largest.. | |
| 08/01 | BioMarin Announces Stable and Durable Annualized Bleed Control for ROCTAVIAN™ in .. | |
| 08/01 | Biomarin Pharmaceutical Inc. Announces Stable and Durable Annualized Bleed Control for .. | |
| 05/01 | Biomarin To Present At 41st Annual J : 30 am PT 1:30 pm ET, in San Francisco, CA | |
| 04/01 | Biomarin To Present At 41st Annual J : 30 am PT /1:30 pm ET, in San Francisco, CA | |
| 03/01 | European Medicines Agency Validates Application for Extension of Indication for VOXZOGO.. | |
| 03/01 | BioMarin Pharmaceutical Inc. Announces That the European Medicines Agency Validated Its.. | |
| 2022 | Cronache di Borsa - Martedì 27 dicembre |  |
| 2022 | 4 minutos de mercados - Martes 27 de diciembre |  |
| 2022 | MarketScreener's World Press Review: December 27 | |
| 2022 | Biomarin Pharmaceutical Inc : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Y.. | |
| 2022 | BioMarin Announces Advancements in FDA Review of ROCTAVIAN for Adults with Severe Hemop.. | |
| 2022 | Sector Update: Health Care Stocks Advancing Wednesday Afternoon | |
| 2022 | Sector Update: Health Care Stocks Still Advancing in Wednesday Trading | |
| 2022 | BioMarin Pharmaceutical Says US FDA No Longer Holding Meeting to Discuss Application fo.. | |
| 2022 | BioMarin : FDA Drops Plans for AdCom Meeting on Hemophilia A Drug | |
| 2022 | BioMarin Pharmaceutical Says FDA Cancels Advisory Meeting for Company's Biologics Licen.. | |
| 2022 | BioMarin Announces Advancements in FDA Review of ROCTAVIAN™ (Valoctocogene Roxapa.. | |
| 2022 | BioMarin Pharmaceutical Inc. Announces Advancements in FDA Review of ROCTAVIAN™ (V.. | |
| 2022 | BioMarin Announces Incremental Progress on Biologics License Application Review for Val.. | |
| 2022 | BioMarin Announces Incremental Progress on Biologics License Application (BLA) Review f.. | |
| 2022 | BioMarin Pharmaceutical Inc. Announces Incremental Progress on Biologics License Applic.. | |
| 2022 | Insider Sell: Biomarin Pharmaceutical | |
| 2022 | BioMarin to Participate in Two Upcoming Investor Conferences | |
| 2022 | BIOMARIN PHARMACEUTICAL INC Management's Discussion and Analysis of Financial Conditio.. | |
| 2022 | Sector Update: Health Care Stocks Still Floundering in Late Trade | |
| 2022 | Sector Update: Healthcare | |
| 2022 | BioMarin Pharmaceutical Q3 Loss Shrinks as Revenue Advances; FY2022 Outlook Reiterated;.. | |
| 2022 | Biomarin : Q3 Earnings Snapshot | |
| 2022 | Biomarin Pharmaceutical : Financial Highlights (in millions of U.S. dollars, except per sh.. | |
| 2022 | BioMarin Pharmaceutical Q3 Loss Shrinks as Revenue Advances; FY2022 Outlook Reiterated | |
| 2022 | Earnings Flash (BMRN) BIOMARIN PHARMACEUTICAL Posts Q3 Revenue $505.3M, vs. Street Est .. | |
| 2022 | BioMarin Announces Third Quarter 2022 Year-over-Year Total Revenue Growth of 24% (31% E.. | |
| 2022 | BioMarin Pharmaceutical Inc. Reaffirms Earnings Guidance for the Year 2022 | |
| 2022 | BioMarin Pharmaceutical Inc. Reports Earnings Results for the Third Quarter and Nine Mo.. | |
| 2022 | Earnings Reaction History: Biomarin Pharmaceutical, 20.0% Foll.. | |
| 2022 | BioMarin Says FDA Accepts BLA for Hemophilia A Therapy | |
| 2022 | BioMarin Pharmaceutical's Hemophilia A Biologics License Application Resubmission Accep.. | |
| 2022 | FDA Accepts BioMarin's Biologics License Application (BLA) for Valoctocogene Roxaparvov.. | |
| 2022 | FDA Accepts Biomarin's Biologics License Application for Valoctocogene Roxaparvovec Aav.. | |
| 2022 | ANALYSEN DES TAGES von Dow Jones Newswires (12.10.2022) |  |
| 2022 | Biomarin Pharmaceutical Inc : Costs Associated with Exit or Disposal Activities (form 8-K) | |
| 2022 | BioMarin Pharmaceutical to Lay Off 120 Staff as Part of Restructuring | |
| 2022 | BioMarin Simplifies Organizational Structure to Increase Efficiency | |
| 2022 | Biomarin Pharmaceutical Inc. to Involve Reduction in Force of Approximately 120 Employe.. | |
| 2022 | Biomarin To Host Third Quarter 2022 : 30pm ET | |
| 2022 | BioMarin Resubmits Biologics License Application for Valoctocogene Roxaparvovec AAV Gen.. | |
| 2022 | BioMarin Pharmaceutical Resubmits Gene Therapy License Application for Severe Hemophili.. | |
| 2022 | BioMarin Resubmits Biologics License Application (BLA) for Valoctocogene Roxaparvovec A.. | |
| 2022 | BioMarin's Gene Therapy for Adults with Severe Hemophilia A, ROCTAVIAN, Assessed to Pro.. | |
| 2022 | BioMarin's Gene Therapy for Adults with Severe Hemophilia A, ROCTAVIAN™ (valoctoc.. | |
| 2022 | Bristol-Myers, Gilead rise, SVB Financial, BioMarin fall | |
| 2022 | BioMarin Pharmaceutical Shares Fall After Company Initiates Probe Into Leukemia Case in.. | |
| 2022 | Biomarin Pharmaceutical Inc : Regulation FD Disclosure (form 8-K) | |
| 2022 | BioMarin Pharmaceutical Inc. - First Gene Therapy for Adults with Severe Hemophilia A, .. | |
| 2022 | BioMarin Pharmaceutical's Roctavian Gets European Nod for Severe Hemophilia A | |
| 2022 | BioMarin Pharmaceutical's Gene Therapy Treatment for Hemophilia A Receives Conditional .. | |
Google
Twitter
Facebook
Apple
English (USA)
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Italiano
Nederlands (Nederland)
Nederlands (België)
bourse
Rapport
